Given the growing evidence that obesity is associated with increased cardiovascular risk, a recent study assessed the impact of semaglutide on cardiovascular outcomes in patients who are overweight or obese but do not have diabetes. Not only did semaglutide reduce the risk of cardiovascular death, myocardial infarction, and stroke by 20 percent, but it also significantly reduced the risk of developing diabetes. Dive further into the findings and implications with Dr. Carol Wysham and study author Dr. Michael Lincoff.
Facing Formidable Diabetic Cases with Patient Persistence & Adherence
Managing Diabetes & COVID-19 in the Wintertime
Caring for Diabetic Patients During the COVID-19 Pandemic
Anti-inflammatory, Anti-atherogenic and Cardioprotective Effects of Insulin
Physiologic Fundamentals of Impaired Glucose Metabolism
Postprandial Blood Glucose: Diabetes Control & Complications
Growing Concerns of Diabetes and Various Cancers
Diabetes Health Care Disparities in the African American Community
Updates in the Classification & Diagnosis of Type 2 Diabetes
Attaining the Best Glucose Control Safely
The Regulatory Environment for the Artificial Pancreas
Recommendations in the Diagnosis and Treatment of Gestational Diabetes
Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance
How Similar Are Biosimilar Insulins?
Sexual Complications and Diabetes
What Do Young Doctors Know About Diabetes Management?
Insulin Pump Practices
Inpatient and Outpatient Recommendations for Diabetes
Psychological Insulin Resistance
Antipsychotics and Metabolic Syndrome
Create your
podcast in
minutes
It is Free
RenaissanceOnlineRadio.com
Men in Lead Aprons
Denver Underground
Exercise: Learn To Love (Or At Least Like) It
NASACast Video